Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Charles River Laboratories collaborates with a drug discovery start-up

by Aayushi Pratap
July 29, 2024 | A version of this story appeared in Volume 102, Issue 23

 

The drug services company Charles River Laboratories has invested in and partnered with Autobahn Labs, a Palo Alto–based drug discovery start-up, to accelerate academic research in novel therapies. Charles River will help Autobahn partner with top academic institutions as well as grant access to its in-house drug discovery and development capabilities. Charles River’s investment was part of a fundraising round led by Autobahn’s founding investor, Samsara BioCapital.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.